114
Participants
Start Date
August 16, 2022
Primary Completion Date
August 31, 2024
Study Completion Date
August 31, 2024
OPL-0401 Dose 1
Pharmaceutical Form: Capsule; Route of Administration: Oral
Placebo
Pharmaceutical Form: Capsule; Route of Administration: Oral
The Retina Care Center, Baltimore
North Carolina Retina Associates, Wake Forest
Charleston Neuroscience Institute, Ladson
Mid Florida Eye Center, Mt. Dora
Retina Associates of Michigan, Grand Blanc
Eye Associates of Northeast Louisiana, West Monroe
Texas Retina Associates, Dallas
Retina Consultants of Texas, The Woodlands
Medical Center Ophthalmology Associates, San Antonio
Valley Retina Institute, PA, McAllen
Austin Retina Associates - Round Rock, Round Rock
Austin Retina Associates, Austin
Austin Clinical Research, LLC, Austin
Panorama Eye Care, LLC, Fort Collins
Retina Associates of Utah, Salt Lake City
Retina Consultants of Southern California, Riverside
Southern California Permanente Medical Group, Riverside
California Retina Consultants, Santa Barbara
Northern California Retina Vitreous Associates, Mountain View
Retinal Consultants Medical Group, Sacramento
Pacific Northwest Retina, Seattle
Spokane Eye Clinical Research, Spokane
Massachussetts Eye and Ear, Boston
Vision Research Center Eye Associates of New Mexico, Albuquerque
Strategic Clinical Research Group LLC, Willow Park
Valo Health, Inc.
INDUSTRY